Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.00
Ask: 2.10
Change: -0.10 (-4.65%)
Spread: 0.10 (5.00%)
Open: 2.15
High: 2.15
Low: 2.05
Prev. Close: 2.15
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Jun 2017 10:37

RNS Number : 4170J
Shield Therapeutics PLC
28 June 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SHIELD THERAPEUTICS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

ü

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

W. HEALTH LP

4. Full name of shareholder(s)  (if different from 3.):iv

HARGREAVE HALE NOMINEES LIMITED

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

28th JUNE 2017

6. Date on which issuer notified:

28th JUNE 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

49% to 48%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB00BYV81293

54,062,901

54,062,901

56,008,541

56,008,541

48.24%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

56,008,541

48.24%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Shares held by Hargreave Hale Nominees Limited

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Matthew Edwards (on behalf of W. Health L.P.)

15. Contact telephone number:

0203 620 2000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFPMLTMBJTMJR
Date   Source Headline
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension
26th Jul 20197:00 amRNSFDA approves Feraccru® with a broad label
2nd Jul 201912:00 pmRNSAdditional Listing
13th Jun 20192:16 pmRNSResult of AGM
3rd Jun 20197:00 amRNSUpdate on Legal Proceedings
13th May 201912:00 pmEQSHardman & Co Research: Shield Therapeutics (STX): All in the execution
8th May 20197:00 amRNSAppointment of Joint Broker
2nd May 20197:00 amRNSInvestor presentation
1st May 201911:58 amRNSAdditional Listing
30th Apr 20197:00 amRNS2018 Annual Report and 2019 AGM Notice
26th Apr 20196:05 pmRNSPDMR Acquisition of Shares
24th Apr 20197:00 amRNSMajor extension to approval in Switzerland
17th Apr 20195:06 pmRNSGrant of share options
17th Apr 20195:01 pmRNSPDMR Acquisition of Shares and Additional Listing
17th Apr 20194:56 pmRNSPDMR Acquisition of Shares
11th Apr 20194:40 pmRNSHolding(s) in Company
8th Apr 20193:42 pmRNSAdditional Listing
3rd Apr 20197:00 amRNSFinal Results
1st Apr 20195:44 pmRNSAdditional Listing
1st Apr 201912:00 pmRNSChange of Adviser
27th Mar 20197:00 amRNSNotice of Results
14th Mar 20193:31 pmRNSPositive decision on Feraccru®'s process patent
4th Mar 20197:00 amRNSPositive results for Feraccru® in AEGIS-H2H study
29th Jan 20197:00 amRNSPositive results of AEGIS-CKD study
28th Jan 20197:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24th Jan 20197:00 amRNSBusiness and trading update
23rd Jan 201910:19 amRNSInvestor presentations
22nd Jan 20197:00 amRNSAppointment of Chairman
13th Dec 20187:00 amRNSUS New Drug Application PDUFA date for Feraccru
5th Dec 201810:04 amRNSUK launch of Feraccru® by Norgine
3rd Dec 20187:00 amRNSNew Drug Application for Feraccru®
9th Nov 20183:46 pmRNSHolding(s) in Company
8th Nov 20186:21 pmRNSHolding(s) in Company
1st Oct 20181:54 pmRNSNotification Of Major Holdings
1st Oct 20187:00 amRNSSubmission of an NDA for Feraccru® with the FDA
24th Sep 20181:06 pmRNSDirector/PDMR Shareholding
24th Sep 20181:02 pmRNSHolding(s) in Company
19th Sep 20187:14 amRNSLicence for the commercialisation of Feraccru
19th Sep 20187:12 amRNSInterim Results
13th Sep 20187:00 amRNSAEGIS-H2H Completion of Recruitment
26th Jul 20187:00 amRNSAppointment of Non-Executive Director
23rd Jul 20187:00 amRNSBusiness Update
9th Jul 20184:27 pmRNSHoldings in Company
9th Jul 20184:26 pmRNSHoldings in Company
28th Jun 201811:56 amRNSResult of AGM
28th Jun 20187:00 amRNSData from real-world clinical use of Feraccru
14th Jun 20187:00 amRNSPositive top-line results from AEGIS-PAED PK study
5th Jun 20187:00 amRNSDirectorate Change
5th Jun 20187:00 amRNS2017 Annual Report and 2018 AGM Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.